Five quick quizzes: What do you know about pancreatic cancer risk factors, diagnosis, and treatment

The article was written by doctors of Internal Oncology - Radiation Oncology Center - Vinmec Times City International General Hospital.

Pancreatic cancer is the 10th most common new cancer and the fourth leading cause of cancer death in men and women. This quick quiz will test your knowledge of pancreatic cancer risk factors, diagnosis, and how pancreatic cancer.

A. Obesity
B. Chronic pancreatitis
C. Smoking
D. Diabetes

Answer: Smoking is the most common risk factor for pancreatic carcinoma. It is estimated that smoking accounts for up to 30% of pancreatic cancer cases. Diabetes can double your risk of developing pancreatic cancer. Less than 5% of all pancreatic cancers are associated with underlying chronic pancreatitis. In many studies, obesity is associated with a higher incidence of pancreatic cancer.

A. Hereditary nonpolyposis colorectal cancer
B. Familial adenomatous polyposis
C. von Hippel-Lindau syndrome
D. All of the above

Answer: Approximately 5%-10% of patients Pancreatic carcinoma has a genetic predisposition to developing the disease. Genetic disorders that increase the risk of pancreatic cancer include hereditary pancreatitis, multiple endocrine neoplasia, hereditary non-rectal cancer, adenomatous polycystic syndrome and Gardner syndrome. BRCA1 and BRCA2.

A. 12%
B. 18%
C. 24%
D. 30%

Answer: Pancreatic carcinoma is a fatal disease. The median survival time for patients is 4-6 months. The 1-year survival rate for pancreatic cancer patients is only 24% and the 5-year survival rate is 5%. However, patients with neuromas and pancreatic cysts, such as mucinous cystadenomas or papillary endothelial mucinous cysts, have a much better survival rate than patients with pancreatic cancer.

A. CT/Scan
B. Endoscopic ultrasound (EUS)
C. Magnetic resonance imaging
D. PET scan

Answer: Due to the accessibility to the pancreas with the endoscopic ultrasound probe is Therefore, high frequency (7.5-12 MHz) ultrasound can be used to produce very high resolution (sub-millimeter) images. This method has proven to be the most sensitive diagnostic method for pancreatic cancer. Negative endoscopic ultrasonography has almost 100% specificity in excluding the presence of a pancreatic tumor.

A. Leucovorin/5-fluorouracil plus oxaliplatin plus irinotecan (FOLFIRINOX)
B. Gemcitabine
C. Gemcitabine and nab-paclitaxel
D. Gemcitabine, docetaxel and capecitabine

Answer: The NCCN Guidelines recommend FOLFIRINOX (leucovorin/ 5-fluorouracil plus oxaliplatin plus irinotecan) as first-line treatment for patients with locally advanced or metastatic disease who are inoperable in good general condition. The NCCN recommends gemcitabine monotherapy for symptomatic patients with locally advanced or metastatic disease incompetent for surgery with poor generalization. In addition, at the stage of metastatic disease several regimens are also recommended, such as GTX (gemcitabine, docetaxel and capecitabine) and gemcitabine and nab-paclitaxel combination therapy.
Reference article source: medicalnewstoday 2019

MORE:
Pancreatic cancer: Causes, symptoms, diagnosis and treatment Chronic pancreatitis occurs? How dangerous is acute pancreatitis?